Dusa Pharmaceuticals abandons Levulan PDT

October 27, 2008

Wilmington, Mass. - Dusa Pharmaceuticals has stopped developing Levulan photo dynamic therapy for acne, after mid-stage trials failed to show statistically significant results.

Wilmington, Mass.

- Dusa Pharmaceuticals has stopped developing Levulan photo dynamic therapy for acne, after mid-stage trials failed to show statistically significant results, Reuters reports.

The treatment combination, called Levulan PDT, is approved for the treatment of actinic keratoses of the face and scalp. It is also used off-label to treat photodamage.

Related Content:

News